Clinical Trial Update: Efficacy, Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days With Clinical or Confirmed Late-onset Sepsis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Meropenem in infants under 90 days with late-onset sepsis has completed. The update reports on its efficacy, pharmacokinetics, and sa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neonatal Sepsis
• Sepsis

Drugs mentioned

• Meropenem (Merrem) (meropenem)

Snippet

Sponsor: PENTA Foundation | Conditions: Sepsis | Phase 3 | Status: COMPLETED